Cargando…

Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.

Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte....

Descripción completa

Detalles Bibliográficos
Autores principales: Narimiya, Tsuyoshi, Kanzaki, Hiroyuki, Yamaguchi, Yuki, Wada, Satoshi, Katsumata, Yuta, Tanaka, Ken, Tomonari, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861591/
https://www.ncbi.nlm.nih.gov/pubmed/31763378
http://dx.doi.org/10.1016/j.bonr.2019.100228
_version_ 1783471393324662784
author Narimiya, Tsuyoshi
Kanzaki, Hiroyuki
Yamaguchi, Yuki
Wada, Satoshi
Katsumata, Yuta
Tanaka, Ken
Tomonari, Hiroshi
author_facet Narimiya, Tsuyoshi
Kanzaki, Hiroyuki
Yamaguchi, Yuki
Wada, Satoshi
Katsumata, Yuta
Tanaka, Ken
Tomonari, Hiroshi
author_sort Narimiya, Tsuyoshi
collection PubMed
description Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte. Previously, we reported that NF-E2-related factor-2 (Nrf2) activation in osteoclast precursors inhibited osteoclastogenesis and bone destruction via induction of anti-oxidation and thereby attenuated intracellular ROS signaling. However, it still remains unknown whether Nrf2 activation in cells other than osteoclasts give any negative influence on supporting property for osteoclastogenesis. Here we discovered that Nrf2 activation in osteoblasts suppresses indirectly osteoclastogenesis via inhibiting the expression of interleukin-6 (IL-6) which promotes osteoclastogenesis. In this study, 5-aminolevulinic acid hydrochloride (ALA) and sodium ferrous citrate (SFC) was used as the Nrf2 activator. in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels. Furthermore, RANKL expression was augmented by LPS, which was blocked by ALA/SFC treatment. Neutralizing antibody against IL-6 confirmed that LPS-mediated RANKL augmentation was dependent on IL-6 induction. in vivo experiments with LPS-mediated bone destruction in mice, confirmed that augmented IL-6 expression in osteoblasts by immunochemical analysis. ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation. These results suggest that Nrf2 activation in osteoblasts suppress IL-6 and inflammatory bone destruction. The Nrf2 activator acts not only on osteoclasts but also on osteoblasts, in other word, Nrf2 activation indirectly suppresses osteoclastogenesis. In conclusion, the Nrf2 activator exhibits dual inhibitory effects via direct action on osteoclast and indirect action on osteoclast supporting cells.
format Online
Article
Text
id pubmed-6861591
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68615912019-11-22 Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. Narimiya, Tsuyoshi Kanzaki, Hiroyuki Yamaguchi, Yuki Wada, Satoshi Katsumata, Yuta Tanaka, Ken Tomonari, Hiroshi Bone Rep Article Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte. Previously, we reported that NF-E2-related factor-2 (Nrf2) activation in osteoclast precursors inhibited osteoclastogenesis and bone destruction via induction of anti-oxidation and thereby attenuated intracellular ROS signaling. However, it still remains unknown whether Nrf2 activation in cells other than osteoclasts give any negative influence on supporting property for osteoclastogenesis. Here we discovered that Nrf2 activation in osteoblasts suppresses indirectly osteoclastogenesis via inhibiting the expression of interleukin-6 (IL-6) which promotes osteoclastogenesis. In this study, 5-aminolevulinic acid hydrochloride (ALA) and sodium ferrous citrate (SFC) was used as the Nrf2 activator. in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels. Furthermore, RANKL expression was augmented by LPS, which was blocked by ALA/SFC treatment. Neutralizing antibody against IL-6 confirmed that LPS-mediated RANKL augmentation was dependent on IL-6 induction. in vivo experiments with LPS-mediated bone destruction in mice, confirmed that augmented IL-6 expression in osteoblasts by immunochemical analysis. ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation. These results suggest that Nrf2 activation in osteoblasts suppress IL-6 and inflammatory bone destruction. The Nrf2 activator acts not only on osteoclasts but also on osteoblasts, in other word, Nrf2 activation indirectly suppresses osteoclastogenesis. In conclusion, the Nrf2 activator exhibits dual inhibitory effects via direct action on osteoclast and indirect action on osteoclast supporting cells. Elsevier 2019-11-01 /pmc/articles/PMC6861591/ /pubmed/31763378 http://dx.doi.org/10.1016/j.bonr.2019.100228 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Narimiya, Tsuyoshi
Kanzaki, Hiroyuki
Yamaguchi, Yuki
Wada, Satoshi
Katsumata, Yuta
Tanaka, Ken
Tomonari, Hiroshi
Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
title Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
title_full Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
title_fullStr Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
title_full_unstemmed Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
title_short Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
title_sort nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting il-6 expression.
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861591/
https://www.ncbi.nlm.nih.gov/pubmed/31763378
http://dx.doi.org/10.1016/j.bonr.2019.100228
work_keys_str_mv AT narimiyatsuyoshi nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression
AT kanzakihiroyuki nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression
AT yamaguchiyuki nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression
AT wadasatoshi nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression
AT katsumatayuta nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression
AT tanakaken nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression
AT tomonarihiroshi nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression